{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:27:57Z","timestamp":1789014477902,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81571218"],"award-info":[{"award-number":["81571218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It is well demonstrated that immunosuppressants can reduce, but not eliminate the risk of generalized development in ocular myasthenia gravis (OMG). In this study, we aimed to explore the predictive factors of generalized conversion of OMG patients who received immunosuppressive treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>OMG patients under immunosuppressive treatments in Tangdu Hospital from June 2008 to June 2012 were retrospectively reviewed. Baseline clinical characteristics were documented. Patients were followed up regularly by face-to-face interview and the main outcome measure was generalized conversion. The logistic regression analysis was performed to determine the predictive factors of generalization of OMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two hundred twenty-three eligible OMG patients completed the final follow-up visit and 38 (17.0%) progressed to generalized MG (GMG) at a median time to generalization of 0.9\u2009year. Patients with adult onset and positive repetitive nerve stimulation (RNS) of facial or axillary nerve had higher conversion rate than those with juvenile onset and negative RNS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015, respectively). Adult-onset patients converted earlier than juvenile-onset OMG patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014). Upon multivariate logistic regression analysis, age of onset (Odds ratio [OR] 1.023, 95% confidence interval [CI] 1.006\u20131.041,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007) and positive facial nerve RNS (OR 2.826, 95%CI 1.045\u20135.460,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038) were found to be positively associated with generalized development. Moreover, an obviously negative association was found for disease duration (OR 0.603, 95%CI 0.365\u20130.850,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Age of onset, disease duration and facial nerve RNS test can predict generalized conversion of OMG under immunosuppressive therapy. Adult-onset, shorter disease duration and facial nerve RNS-positive OMG patients have a higher risk of generalized development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-020-01805-1","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T03:02:30Z","timestamp":1591844550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China"],"prefix":"10.1186","volume":"20","author":[{"given":"Jiaqi","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-881X","authenticated-orcid":false,"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"issue":"5","key":"1805_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever Jr","year":"1983","unstructured":"Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol. 1983;14(5):516\u20139.","journal-title":"Ann Neurol"},{"issue":"2","key":"1805_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60(2):243\u20138.","journal-title":"Arch Neurol"},{"issue":"6","key":"1805_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0188-4409(02)00405-8","volume":"33","author":"JM Remes-Troche","year":"2002","unstructured":"Remes-Troche JM, T\u00e9llez-Zenteno JF, Esta\u00f1ol B, Gardu\u00f1o-Espinoza J, Garc\u00eda-Ramos G. Thymectomy in myasthenia gravis: response, complications, and associated conditions. Arch Med Res. 2002;33(6):545\u201351.","journal-title":"Arch Med Res"},{"issue":"2","key":"1805_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62(2):156\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1805_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1600-0404.2005.00374.x","volume":"111","author":"F Romi","year":"2005","unstructured":"Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand. 2005;111(2):134\u201341.","journal-title":"Acta Neurol Scand"},{"issue":"1\u20132","key":"1805_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","volume":"273","author":"YH Hong","year":"2008","unstructured":"Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273(1\u20132):10\u20134.","journal-title":"J Neurol Sci"},{"issue":"5","key":"1805_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","volume":"57","author":"KY Teo","year":"2018","unstructured":"Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang L, Yew Long LO, et al. Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve. 2018;57(5):756\u201360.","journal-title":"Muscle Nerve"},{"issue":"12","key":"1805_CR8","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","volume":"265","author":"F Li","year":"2018","unstructured":"Li F, Hotter B, Swierzy M, Ismail M, Meisel A, R\u00fcckert JC. Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol. 2018;265(12):2773\u201382.","journal-title":"J Neurol"},{"issue":"3","key":"1805_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/mus.21555","volume":"41","author":"JA Allen","year":"2010","unstructured":"Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve. 2010;41(3):379\u201384.","journal-title":"Muscle Nerve"},{"issue":"9","key":"1805_CR10","first-page":"1117","volume":"94","author":"S Leeamornsiri","year":"2011","unstructured":"Leeamornsiri S, Chirapapaisan N, Chuenkongkaew W. Clinical profiles of Thai patients with ocular myasthenia gravis in Siriraj hospital. J Med Assoc Thail. 2011;94(9):1117\u201321.","journal-title":"J Med Assoc Thail"},{"key":"1805_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-2-44","volume":"2","author":"VC Juel","year":"2007","unstructured":"Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.","journal-title":"Orphanet J Rare Dis"},{"key":"1805_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","volume":"9","author":"X Huang","year":"2018","unstructured":"Huang X, Li Y, Feng H, Chen P, Liu W. Clinical characteristics of juvenile myasthenia gravis in southern China. Front Neurol. 2018;9:77.","journal-title":"Front Neurol"},{"issue":"4","key":"1805_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00415-015-7638-2","volume":"262","author":"M Gui","year":"2015","unstructured":"Gui M, Luo X, Lin J, Li Y, Zhang M, Zhang X, et al. Long-term outcome of 424 childhood-onset myasthenia gravis patients. J Neurol. 2015;262(4):823\u201330.","journal-title":"J Neurol"},{"issue":"1","key":"1805_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1600-0404.1992.tb08056.x","volume":"86","author":"V Wong","year":"1992","unstructured":"Wong V, Hawkins BR, Yu YL. Myasthenia gravis in Hong Kong Chinese. 2. Paediatric disease. Acta Neurol Scand. 1992;86(1):68\u201372.","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"1805_CR15","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1212\/WNL.42.10.1888","volume":"42","author":"LH Phillips 2nd","year":"1992","unstructured":"Phillips LH 2nd, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42(10):1888\u201393.","journal-title":"Neurology"},{"issue":"4","key":"1805_CR16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mus.25971","volume":"57","author":"SK Kamarajah","year":"2018","unstructured":"Kamarajah SK, Sadalage G, Palmer J, Carley H, Maddison P, Sivaguru A. Ocular presentation of myasthenia gravis: a natural history cohort. Muscle Nerve. 2018;57(4):622\u20137.","journal-title":"Muscle Nerve"},{"issue":"19","key":"1805_CR17","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.4103\/0366-6999.166032","volume":"128","author":"LL Wang","year":"2015","unstructured":"Wang LL, Zhang Y, He ML. Clinical features and prognosis of ocular myasthenia gravis patients with different phenotypes. Chin Med J. 2015;128(19):2682\u20134.","journal-title":"Chin Med J"},{"issue":"4","key":"1805_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/ene.12057","volume":"20","author":"H Zach","year":"2013","unstructured":"Zach H, Cetin H, Hilger E, Paul A, Wuschitz B, Jung R, et al. The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur J Neurol. 2013;20(4):708\u201313.","journal-title":"Eur J Neurol"},{"issue":"7","key":"1805_CR19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology. 2015;122(7):1517\u201321.","journal-title":"Ophthalmology"},{"issue":"2","key":"1805_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"NT Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217(2):131\u20133.","journal-title":"J Neurol Sci"},{"issue":"4","key":"1805_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ajo.2010.05.002","volume":"150","author":"SL Pineles","year":"2010","unstructured":"Pineles SL, Avery RA, Moss HE, Finkel R, Blinman T, Kaiser L, et al. Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol. 2010;150(4):453\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1805_CR22","first-page":"181","volume":"17","author":"KM McCreery","year":"2002","unstructured":"McCreery KM, Hussein MA, Lee AG, Paysse EA, Chandran R, Coats DK. Major review: the clinical spectrum of pediatric myasthenia gravis: blepharoptosis, ophthalmoplegia and strabismus. A report of 14 cases. Binocul Vis Strabismus Q. 2002;17(3):181\u20136.","journal-title":"Binocul Vis Strabismus Q"},{"issue":"1","key":"1805_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/01616412.2018.1525121","volume":"41","author":"L Fan","year":"2019","unstructured":"Fan L, Ma S, Yang Y, Yan Z, Li J, Li Z. Clinical differences of early and late-onset myasthenia gravis in 985 patients. Neurol Res. 2019;41(1):45\u201351.","journal-title":"Neurol Res"},{"issue":"1","key":"1805_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018;128(1):15\u201324.","journal-title":"Int J Neurosci"},{"issue":"3","key":"1805_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13760-018-0943-7","volume":"118","author":"G Galassi","year":"2018","unstructured":"Galassi G, Mazzoli M, Ariatti A, Kaleci S, Valzania F, Nichelli PF. Antibody profile may predict outcome in ocular myasthenia gravis. Acta Neurol Belg. 2018;118(3):435\u201343.","journal-title":"Acta Neurol Belg"},{"key":"1805_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019;205:99\u2013105.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1805_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000311012","volume":"35","author":"CH Lai","year":"2010","unstructured":"Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology. 2010;35(1):66\u201371.","journal-title":"Neuroepidemiology"},{"issue":"2","key":"1805_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141\u20139.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1805_CR29","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s10439-010-0207-z","volume":"39","author":"J Rodr\u00edguez","year":"2011","unstructured":"Rodr\u00edguez J, Dimitrova NA, Dimitrov GV, Gila L. Shape variability of potentials recorded by a single-fiber electrode and its effect on jitter estimation. Ann Biomed Eng. 2011;39(2):812\u201323.","journal-title":"Ann Biomed Eng"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01805-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01805-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01805-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T19:33:35Z","timestamp":1623353615000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01805-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1805"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01805-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22008\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocols were approved by the ethics committees of Tangdu Hospital, Fourth Military Medical University. Written informed consent was obtained from all patients participating in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}